[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:neurogenic-detrusor-overactivity":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":22,"states":23},"Neurogenic detrusor overactivity",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06596291","Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:55.355429Z","2026-05-05T02:35:31.752235Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT05491525","Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to \u003C 18 Years of Age With NDO and on CIC",[19],"Phase 2\u002FPhase 3","2026-08-26T02:17:46.653867Z","2026-06-16T05:54:07.909619Z",[],[]]